Kymera Therapeutics, Inc.

This early-stage study tested an oral medication called KT-621 in 22 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check the drug's safety and how the body handles it. Researchers monitored side effects and drug levels in the blood. This is a fir…

This early-stage study tested the safety of a new oral drug, KT-621, in 118 healthy adults aged 19 to 55. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The goal was not to treat any disease, but to gather ess…